SBI Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

SBI Securities’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.98K	Sell	52 -2	-4%	-$110	﹤0.01%	2409
2026 Q1	$3.05K	Sell	54 -10	-16%	-$583	﹤0.01%	2248
2025 Q4	$3.8K	Sell	64 -4	-6%	-$218	﹤0.01%	2136
2025 Q3	$3.68K	Buy	68 +34	+100%	+$1.94K	﹤0.01%	2177
2025 Q2	$1.87K	Sell	34 -10	-23%	-$589	﹤0.01%	2412
2025 Q1	$3.11K	Sell	44 -500	-92%	-$33.6K	﹤0.01%	2098
2024 Q4	$35.8K	Buy	+544	New	+$36.4K	﹤0.01%	1095

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

SBI Securities's BMRN Position: Q2 2026 in Review

SBI Securities reduced its BioMarin Pharmaceuticals (BMRN) stake by 3.7% in Q2 2026, selling an estimated $110 and leaving 52 shares worth $2.98K. The position accounts for ﹤0.01% of the portfolio, ranked #2409.

SBI Securities first reported a position in BMRN in Q4 2024 and has held it in 7 quarters since. The position peaked at $35.8K in Q4 2024. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

SBI Securities held 52 shares of BioMarin Pharmaceuticals worth $2.98K as of Q2 2026.
SBI Securities sold 2 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $110.
BioMarin Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2409 holding.
SBI Securities first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
SBI Securities's BioMarin Pharmaceuticals position peaked at $35.8K in Q4 2024.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.